ホームページへ
820К+ 2014年以降患者がサポートを受けています
50
1,500 クリニック
6K+ レビュー
3K+ 3,000名以上の資格を持つ医師

ポーランドでの乳癌化学療法費用について今すぐご確認ください

ポーランドでの乳癌化学療法の平均価格は$5,000、最低価格は$3,500、最高価格は$6,500です
ポーランドトルコオーストリア
乳癌化学療法から $3,500から $1,200から $15,000
データは2026年May月時点でBookimedにより検証され、世界92件のクリニックからの患者リクエストと公式見積もりに基づいています。中央値費用は実際の請求書(2024年-2026年)に基づいており毎月更新されます。実際の価格は異なる場合があります。

Bookimedでのお客様のメリットと保証

直接価格

Bookimedは乳癌化学療法価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。到着時にクリニックで乳癌化学療法代を直接お支払いいただきます。

検証済みクリニック・医師のみ

Bookimedはお客様の安全に取り組んでいます。乳癌化学療法で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。

無料24時間365日サポート

Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。乳癌化学療法の旅路でお一人になることはありません。

なぜ当社を?

Bookimed専属アシスタント

  • すべての段階でサポート
  • 適切なクリニックと医師の選択をサポート
  • 迅速で便利な情報アクセスを確保

ポーランドでの乳癌化学療法概要

要点
関連手術・費用
仕組みについて
メリット
お支払い
患者様が推奨 -
85%
手術時間 - 2 時間
滞在国での滞在 - 1 日
リハビリテーション - 1 日
麻酔 - 局所麻酔
処理済みリクエスト - 46119
Bookimed手数料 - $0

ポーランドで乳癌化学療法の医学評価を受ける:その分野の最高の専門医をお選びください

すべての医師を見る

Bookimed患者のビデオストーリー

Amanda
My companion and I were treated with such kindness — I have nothing but admiration for the entire team.
治療: 乳房切除術
Randolph
Stay strong, stay informed, and never underestimate the power of cutting-edge treatments and a solid support system.
治療: 肝動脈内放射線療法

このコンテンツを共有

更新済み: 05/27/2022
著者
アンナ・レオノヴァ
アンナ・レオノヴァ
コンテンツマーケティングチーム責任者
10年以上の経験を持つ認定医療ライターで、文学修士号を持ち、世界中の医療専門家のインタビューに基づくBookimedの信頼できるコンテンツを開発しています。
Fahad Mawlood
医学編集者・データサイエンティスト
一般開業医。4つの科学賞受賞。西アジアでの勤務経験。アラビア語を話す患者様をサポートする医療チームの元チームリーダー。現在はデータ処理と医療コンテンツの正確性を担当
Fahad Mawlood Linkedin
このページは、さまざまな国で利用可能な各種医療状態、治療、ヘルスケアサービスに関する情報を掲載する場合があります。コンテンツは情報提供のみを目的として提供されており、医療アドバイスやガイダンスとして解釈されるべきではないことをご承知おきください。医療治療を開始または変更する前に、医師または資格のある医療専門家にご相談ください。

ポーランドでの乳癌化学療法に関するFAQ

これらのFAQはBookimedを通じて医療支援を求める実際の患者からのものです。回答は経験豊富な医療コーディネーターと信頼できるクリニック代表者が行います。

Is chemotherapy free in Poland?

Chemotherapy is free for Polish citizens, residents, and legally employed foreigners through the National Health Fund (NFZ). European Union residents with EHIC cards and Ukrainian refugees with PESEL numbers also qualify. Private treatment options are available for those seeking faster access outside public waiting lists.

  • Public coverage: NFZ covers standard chemotherapy drugs, hospital stays, and oncological surgeries.
  • Private costs: Private cycles cost $2,000 to $4,000 for those without insurance.
  • Wait times: Public system queues can range from 3 to 6 months post-diagnosis.
  • Extra expenses: Patients often pay for supportive anti-nausea medications and specialized nutrition.

Bookimed Expert Insight: Many patients choose hybrid care to bypass long public oncology queues. You can start initial diagnostics at specialized centers like European Health Center Otwock. This center offers unique interdisciplinary cardio-oncology care for complex cases. Starting privately ensures immediate treatment while waiting for public system enrollment.

Patient Consensus: Patients report that while chemotherapy is officially free, extra costs for medications add up. Many suggest budgeting for private diagnostic scans to speed up the treatment start date.

What are the most common chemotherapy side effects reported by Polish patients?

Polish patients undergoing chemotherapy for breast cancer frequently report severe fatigue, gastrointestinal issues, and hair loss as the most burdensome side effects. Neutropenia causes over 80% of treatment delays, while nearly 74% of patients find daily functioning moderately or severely impaired during active treatment cycles.

  • Hematological impact: Neutropenia is a primary side effect causing most treatment deferrals in Polish cohorts.
  • Physical symptoms: Nearly 100% of hospitalized patients report profound weakness and bone-deep fatigue.
  • Dermatological effects: Alopecia affects approximately 68% of patients, presenting a significant emotional and physical challenge.
  • Gastrointestinal issues: Nausea and loss of taste are highly prevalent despite improvements in antiemetic care.

Bookimed Expert Insight: Specialized facilities like the European Health Center Otwock focus on cardioprotective oncology. This is vital since 31.7% of survivors develop circulatory issues. Their interdisciplinary approach helps manage long-term side effects that often surprise patients after treatment ends. Choosing a clinic with proactive cardio-oncology care can significantly improve long-term recovery outcomes.

Patient Consensus: Fatigue is often underestimated and peaks around 3 to 5 days after infusion. Patients recommend managing early nausea preventatively and planning for cognitive fog, often called chemo brain, which persists for weeks.

What guidelines do Polish oncologists follow for breast-cancer chemotherapy?

Polish oncologists follow standardized protocols strictly aligned with the European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN). These guidelines are adapted by the Polish Society of Clinical Oncology (PTOK) to ensure global standards meet local healthcare regulations.

  • International standards: Polish protocols mirror ESMO and NCCN benchmarks for high-precision treatment.
  • Administrative speed: The DiLO card guarantees patients start chemotherapy within 14 days of consultation.
  • Regimen specifics: Doctors utilize anthracycline-based therapies and taxanes for standard early-stage breast cancer.
  • Cardio-oncology focus: Specialized centers like European Health Center Otwock monitor heart health during chemotherapy.

Bookimed Expert Insight: While public hospitals follow domestic PTOK guidelines, patients often turn to private facilities to bypass the typical 4-6 week postoperative wait. Leading clinics like European Health Center Otwock provide faster access to personalized molecular diagnostics. This speed is critical for triple-negative cases where early intervention significantly improves results.

Patient Consensus: Patients report that while public care is reliable, switching to private treatment initially helps avoid delays. Many emphasize requesting the specific PTO guidelines and monitoring cardiotoxicity during aggressive regimens.

Where are Poland's leading oncology centers for breast-cancer chemotherapy?

Poland's leading breast cancer chemotherapy centers include the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw and the University Clinical Hospital. Specialized facilities like European Health Center Otwock provide advanced drug therapies. These centers offer high-referential level care and integrated multidisciplinary oncology teams.

  • Certification standards: Top facilities hold European Commission Initiative on Breast Cancer (ECIBC) accreditation.
  • Specialized departments: European Health Center Otwock manages treatment-related heart risks in cardio-oncology units.
  • Regional leadership: Lower Silesian Oncology Center provides comprehensive chemo and psychological support services.
  • Expert staffing: Dr. Andrzej Wronski at Otwock leads personalized chemotherapy for complex cases.

Bookimed Expert Insight: While public university hospitals in Warsaw or Krakow manage the highest patient volumes, private centers like European Health Center Otwock provide a critical advantage. Their unique focus on cardio-oncology protects patients from heart damage common with aggressive chemotherapy drugs.

Patient Consensus: Patients recommend requesting written treatment plans early and verifying drug availability. Scheduling wait times can be long, so many suggest seeking expedited pathways in major cities.

What is a DiLO card and how does it help cancer patients in Poland?

The DiLO card is an Oncology Diagnosis and Treatment Card issued by Polish physicians to fast-track cancer care. It functions as a green corridor within the healthcare system. It guarantees maximum waiting times for diagnostics and ensures coordinated treatment plans through the National Health Fund.

  • Fast-tracked diagnostics: Initial cancer screening and confirmation must occur within 28 days of issuance.
  • Specialized consilium: A multidisciplinary team of specialists designs a personalized treatment plan for patients.
  • Oncology coordinator: Dedicated staff manage scheduling and administrative formalities throughout the treatment journey.
  • Funding priority: Procedures under this scheme bypass standard financial caps for uninterrupted clinical access.

Bookimed Expert Insight: DiLO cards significantly accelerate access to specific biologics. Data reveals patients with aggressive breast cancer types start trastuzumab therapy up to 60 days sooner. Centers like European Health Center Otwock leverage these pathways to integrate interdisciplinary cardio-oncology care for safer chemotherapy administration.

Patient Consensus: Patients emphasize applying immediately after diagnosis. They report that using the card often covers 80-100% of costs at partner facilities. Many recommend tracking the application online via the NFZ portal to manage potential bureaucratic delays.

無料相談を受ける

最適な連絡方法をお選びください